Lucasbio
Clinical trials sponsored by Lucasbio, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Donor t cells aim to fight severe COVID-19 Results expected Oct 2026 (estimated)
- Immune cells engineered to hunt viruses show promise for transplant kids Results expected May 2027 (estimated)
- Donor cells take on Drug-Resistant viruses in new trial Results expected Jun 2027 (estimated)
- Personalized immune cells take aim at Drug-Resistant eye virus Results expected Aug 2027 (estimated)
-
Immune cells engineered to hunt viruses show promise for transplant kids
Disease control Recruiting nowThis study tests a new cell therapy called LB-DTK-MV in children aged 1-25 who have stubborn viral infections (CMV, EBV, or BKV) after a stem cell transplant. The therapy uses specially grown immune cells from a donor to attack the viruses. Participants receive two infusions two …
Sponsor: LucasBio • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Personalized immune cells take aim at Drug-Resistant eye virus
Disease control Recruiting nowThis study tests a new treatment called LB-DTK-CMV for people with cytomegalovirus (CMV) retinitis that has not responded to standard antiviral medicines. The treatment uses a patient's own immune cells, specially trained to attack CMV, and is given as two infusions. The trial ai…
Sponsor: LucasBio • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Donor cells take on Drug-Resistant viruses in new trial
Disease control Recruiting nowThis early-phase trial tests a treatment called LB-DTK-MV, which uses immune cells from a healthy donor to fight three viruses (CMV, BKV, and EBV) that have become resistant to standard antiviral drugs. The study includes 27 adults who have had a stem cell transplant or certain c…
Phase 1/2 • Sponsor: LucasBio • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC